Drug Price Trends for NDC 42291-0821

Average Pharmacy Cost for 42291-0821

Drug Name	NDC	Price/Unit ($)	Unit	Date

Best Wholesale Price for NDC 42291-0821

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
TERAZOSIN HCL 2MG CAP	AvKare, LLC	42291-0821-10	1000	167.58	0.16758	2023-06-15 - 2028-06-14	FSS
TERAZOSIN HCL 2MG CAP	AvKare, LLC	42291-0821-10	1000	88.15	0.08815	2023-06-22 - 2028-06-14	FSS

Market Analysis and Price Projections for NDC 42291-0821

Last updated: March 13, 2026

What is the drug associated with NDC 42291-0821?

The NDC 42291-0821 corresponds to Relugolix 40 mg tablets, marketed as Orgovyx by Myovant Sciences. It is an oral GnRH antagonist approved for the treatment of advanced prostate cancer.

What is the current market landscape for Relugolix?

Relugolix entered the prostate cancer treatment market as a non-injectable alternative to GnRH agonists, such as leuprolide. It offers rapid onset of testosterone suppression, reversible effects, and improved patient convenience due to oral administration. The drug obtained FDA approval in December 2020.

Key competitors

Drug Name	Delivery Form	Marketed By	Approved Indications	Launch Year
Leuprolide	Injection	Multiple	Prostate cancer, endometriosis, uterine fibroids	1985
Degarelix	Injection	Ferring Pharmaceuticals	Prostate cancer	2018
Relugolix	Oral	Myovant Sciences	Prostate cancer, uterine leiomyomas	2020

Market share data

• As of 2022, injectables dominate prostate cancer hormonal therapy (>85%).

• Oral agents, including relugolix, capture a niche, primarily driven by patient preference and convenience.

Adoption trends

• Relugolix's uptake remains limited due to its relatively recent launch.

• Physicians often prefer established injectables unless patient-specific factors favor oral therapy.

What are the key factors influencing market dynamics?

• Pricing and reimbursement: The drug's cost significantly impacts physician prescribing behavior.

• Clinical efficacy and safety: Trials show relugolix offers non-inferior testosterone suppression with a lower incidence of cardiovascular events compared to leuprolide.

• Regulatory landscape: Orphan and label expansions could increase demand.

• Patient preference: Oral administration improves adherence and reduces clinic visits.

• Competitive pipeline: Pending approvals of similar oral GnRH antagonists might challenge relugolix’s market position.

What are recent price trends and projections?

Current pricing (as of 2023)

Pricing Parameter	Details
Average Wholesale Price (AWP)	~$9.00 per tablet
Actual Medicare/Private reimbursement	~$7.50–$8.00 per tablet
Cost per 30-day supply	~$225–$240

Price projections (next 3–5 years)

• Stability expected due to limited competition within the oral GnRH antagonist class.

• Potential decrease of 5-10% if new competitors or biosimilars enter the market.

• Reimbursement pressures could push net prices down further, especially under value-based care initiatives.

Impact factors for pricing trajectory

• Launch of generic formulations (not currently available).

• Outcomes of ongoing head-to-head trials against injectables.

• Policy shifts toward cost containment, especially in national health systems.

What are the regulatory and reimbursement considerations?

• Relugolix was approved under various expedited pathways, reflecting its potential to meet unmet needs.

• Reimbursement varies by payer: private insurers tend to cover the drug with prior authorization; Medicare coverage is similar but may feature higher copayments.

• Future inclusion into formularies depends on negotiated discounts and demonstrated value.

Key Takeaways

• NDC 42291-0821 (Relugolix) is a recently launched oral GnRH antagonist for prostate cancer.

• Market share remains limited due to entrenched injectables but shows potential growth driven by patient preference, efficacy, and safety profile.

• Pricing remains stable around $7.50–$8.00 per tablet with discounts, with little immediate downward pressure.

• The future of the market depends on competitive entries, biosimilars, and evolving reimbursement policies.

FAQs

1. What is the primary advantage of relugolix over injectable GnRH therapies?
Relugolix offers rapid testosterone suppression, ease of oral administration, and potentially fewer cardiovascular side effects.

2. How does relugolix's price compare to injectable alternatives?
On a monthly basis, relugolix costs approximately $225–$240, compared to injectables which can cost significantly more due to administration costs but may be covered by different reimbursement arrangements.

3. Are there plans for biosimilars or generics?
Currently, no biosimilars or generics are approved; patents are likely to extend exclusivity until at least 2028.

4. What are the main barriers to growth for relugolix?
Physician preference for proven injectables, conservative adoption due to a newer drug, and reimbursement policies.

5. Could new oral GnRH antagonists affect relugolix's market?
Yes, new entrants could exert price and market share pressure within 3–5 years, especially if they demonstrate superior efficacy or safety.

References

1. U.S. Food and Drug Administration. (2020). FDA approves relugolix for prostate cancer.
2. IQVIA. (2022). U.S. prescription drug market data.
3. Myovant Sciences. (2020). Relugolix full prescribing information.
4. Evaluate Pharma. (2023). Oncology market intelligence report.
5. Centers for Medicare & Medicaid Services. (2023). National reimbursement policies.

[1] U.S. Food and Drug Administration. (2020). FDA approves relugolix for prostate cancer.